Our faculty and staff have a long history of developing innovative diagnostic and treatment approaches for breast cancer. These innovations have included new drug and biomarker development as well as changes in treatment paradigms for the disease.
Among these have been the first use of anthracyclines in the adjuvant and neo-adjuvant setting for primary breast cancer treatment, the change in approach to treatment of locally advanced/inoperable and inflammatory breast cancer, defining the significance of pathologic complete responses, demonstrating the long term survival of metastatic disease patients treated with chemotherapy, and expanding the role of adjuvant endocrine therapies.
Through our clinical research endeavors, we continue to strive to advance the prevention, diagnosis, and treatment of breast cancer. Our faculty and staff are dedicated to providing safe and effective care that will enhance the quality of life for our patients.
Jennifer Litton, M.D., serves as chief of this section.